Annual CFF
$59.29 M
+$49.43 M+501.33%
December 31, 2023
Summary
- As of February 7, 2025, ALXO annual cash flow from financing activities is $59.29 million, with the most recent change of +$49.43 million (+501.33%) on December 31, 2023.
- During the last 3 years, ALXO annual CFF has fallen by -$403.59 million (-87.19%).
- ALXO annual CFF is now -87.19% below its all-time high of $462.88 million, reached on December 31, 2020.
Performance
ALXO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$251.00 K
-$26.90 M-99.08%
September 30, 2024
Summary
- As of February 7, 2025, ALXO quarterly cash flow from financing activities is $251.00 thousand, with the most recent change of -$26.90 million (-99.08%) on September 30, 2024.
- Over the past year, ALXO quarterly CFF has increased by +$362.00 thousand (+326.13%).
- ALXO quarterly CFF is now -99.87% below its all-time high of $188.36 million, reached on December 31, 2020.
Performance
ALXO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$89.66 M
+$362.00 K+0.41%
September 30, 2024
Summary
- As of February 7, 2025, ALXO TTM cash flow from financing activities is $89.66 million, with the most recent change of +$362.00 thousand (+0.41%) on September 30, 2024.
- Over the past year, ALXO TTM CFF has increased by +$80.04 million (+832.06%).
- ALXO TTM CFF is now -80.63% below its all-time high of $462.88 million, reached on December 31, 2020.
Performance
ALXO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ALXO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +501.3% | +326.1% | +832.1% |
| 3 y3 years | -87.2% | +213.8% | +4953.8% |
| 5 y5 years | +10000.0% | -67.7% | -75.0% |
ALXO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +2298.5% | -99.6% | +284.6% | at high | +9973.6% |
| 5 y | 5-year | -87.2% | +2298.5% | -99.9% | +132.6% | -80.6% | +9973.6% |
| alltime | all time | -87.2% | >+9999.0% | -99.9% | +132.6% | -80.6% | -100.0% |
ALX Oncology Holdings Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $251.00 K(-99.1%) | $89.66 M(+0.4%) |
| Jun 2024 | - | $27.15 M(+779.8%) | $89.29 M(+42.9%) |
| Mar 2024 | - | $3.09 M(-94.8%) | $62.48 M(+5.4%) |
| Dec 2023 | $59.29 M(+501.3%) | $59.17 M(<-9900.0%) | $59.29 M(+516.4%) |
| Sep 2023 | - | -$111.00 K(-132.4%) | $9.62 M(+0.3%) |
| Jun 2023 | - | $343.00 K(-420.6%) | $9.59 M(-0.8%) |
| Mar 2023 | - | -$107.00 K(-101.1%) | $9.67 M(-1.9%) |
| Dec 2022 | $9.86 M(+298.9%) | $9.49 M(-7080.9%) | $9.86 M(+1007.9%) |
| Sep 2022 | - | -$136.00 K(-132.2%) | $890.00 K(-39.2%) |
| Jun 2022 | - | $422.00 K(+427.5%) | $1.47 M(-17.4%) |
| Mar 2022 | - | $80.00 K(-84.7%) | $1.77 M(-28.2%) |
| Dec 2021 | $2.47 M | $524.00 K(+19.4%) | $2.47 M(-98.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $439.00 K(-39.9%) | $190.31 M(-47.2%) |
| Jun 2021 | - | $731.00 K(-6.0%) | $360.17 M(+0.4%) |
| Mar 2021 | - | $778.00 K(-99.6%) | $358.67 M(-22.5%) |
| Dec 2020 | $462.88 M(+2914.1%) | $188.36 M(+10.6%) | $462.88 M(+65.1%) |
| Sep 2020 | - | $170.30 M(<-9900.0%) | $280.45 M(+154.6%) |
| Jun 2020 | - | -$769.00 K(-100.7%) | $110.15 M(-8.5%) |
| Mar 2020 | - | $104.99 M(+1671.4%) | $120.35 M(+683.7%) |
| Dec 2019 | $15.36 M(>+9900.0%) | $5.93 M(>+9900.0%) | $15.36 M(+62.9%) |
| Sep 2019 | - | $0.00(-100.0%) | $9.43 M(0.0%) |
| Jun 2019 | - | $9.43 M(>+9900.0%) | $9.43 M(>+9900.0%) |
| Mar 2019 | - | $0.00 | $0.00 |
| Dec 2018 | $1000.00 | - | - |
FAQ
- What is ALX Oncology Holdings annual cash flow from financing activities?
- What is the all time high annual CFF for ALX Oncology Holdings?
- What is ALX Oncology Holdings annual CFF year-on-year change?
- What is ALX Oncology Holdings quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for ALX Oncology Holdings?
- What is ALX Oncology Holdings quarterly CFF year-on-year change?
- What is ALX Oncology Holdings TTM cash flow from financing activities?
- What is the all time high TTM CFF for ALX Oncology Holdings?
- What is ALX Oncology Holdings TTM CFF year-on-year change?
What is ALX Oncology Holdings annual cash flow from financing activities?
The current annual CFF of ALXO is $59.29 M
What is the all time high annual CFF for ALX Oncology Holdings?
ALX Oncology Holdings all-time high annual cash flow from financing activities is $462.88 M
What is ALX Oncology Holdings annual CFF year-on-year change?
Over the past year, ALXO annual cash flow from financing activities has changed by +$49.43 M (+501.33%)
What is ALX Oncology Holdings quarterly cash flow from financing activities?
The current quarterly CFF of ALXO is $251.00 K
What is the all time high quarterly CFF for ALX Oncology Holdings?
ALX Oncology Holdings all-time high quarterly cash flow from financing activities is $188.36 M
What is ALX Oncology Holdings quarterly CFF year-on-year change?
Over the past year, ALXO quarterly cash flow from financing activities has changed by +$362.00 K (+326.13%)
What is ALX Oncology Holdings TTM cash flow from financing activities?
The current TTM CFF of ALXO is $89.66 M
What is the all time high TTM CFF for ALX Oncology Holdings?
ALX Oncology Holdings all-time high TTM cash flow from financing activities is $462.88 M
What is ALX Oncology Holdings TTM CFF year-on-year change?
Over the past year, ALXO TTM cash flow from financing activities has changed by +$80.04 M (+832.06%)